Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACE | P12821 | 6/20 | 0.60 |
| ▸ | REN | P00797 | 2/20 | 0.55 |
| ▸ | MVD | P53602 | 2/20 | 0.47 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.46 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.46 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.46 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11559923 | 0.95 | ACE (0.62) | ACERENMVD | |
| SCHEMBL6783030 | 0.95 | ACE (0.66) | ACERENMVDCHRM2CHRM4 | |
| SCHEMBL6784027 | 0.95 | ACE (0.66) | ACERENMVDCHRM2CHRM4 | |
| SCHEMBL6784032 | 0.95 | ACE (0.66) | ACERENMVDCHRM2CHRM4 | |
| SCHEMBL6789464 | 0.95 | ACE (0.66) | ACERENMVDCHRM2CHRM4 | |
| SCHEMBL7298458 | 0.95 | ACE (0.66) | ACERENMVDCHRM2CHRM4 | |
| SCHEMBL6783037 | 0.95 | ACE (0.66) | ACERENMVDCHRM2CHRM4 | |
| SCHEMBL6789458 | 0.95 | ACE (0.66) | ACERENMVDCHRM2CHRM4 | |
| SCHEMBL6789294 | 0.95 | ACE (0.66) | ACERENMVDCHRM2CHRM4 | |
| Miridesap SCHEMBL6788714 | 0.93 | ACE (0.68) | ACERENMVDCHRM2CHRM4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3057446-B1 | ORGANIC COMPOUNDS HAVING TASTE-MODIFYING PROPERTIES | GIVAUDAN SA (CH) | 2017-12-06 | — | — | EP | claimed |
| US-20160278408-A1 | Organic Compounds | GIVAUDAN S.A. (CH) | 2016-09-29 | — | — | US | claimed |
| EP-3057446-A1 | ORGANIC COMPOUNDS | Givaudan S.A. (CH) | 2016-08-24 | — | — | EP | claimed |
| WO-2015050537-A1 | ORGANIC COMPOUNDS | GIVAUDAN S.A. (CH) | 2015-04-09 | — | — | WO | claimed |
| EP-3057446-B1 | ORGANIC COMPOUNDS HAVING TASTE-MODIFYING PROPERTIES | GIVAUDAN SA (CH) | 2017-12-06 | — | — | EP | disclosed |
| US-20160278408-A1 | Organic Compounds | GIVAUDAN S.A. (CH) | 2016-09-29 | — | — | US | disclosed |
| EP-3057446-A1 | ORGANIC COMPOUNDS | Givaudan S.A. (CH) | 2016-08-24 | — | — | EP | disclosed |
| WO-2015050537-A1 | ORGANIC COMPOUNDS | GIVAUDAN S.A. (CH) | 2015-04-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160278408-A1 | Organic Compounds | CYC1, AOX1, OR10J3 | ACE 1913/4885REN 290/4885MVD 4385/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.